Fevzi Yalniz — University of Kentucky

Education/Academic qualification

Post Doctoral Fellow, University Of Texas School of Allied Health Sciences

2019

Residency, Yeditepe University, Istanbul, Turkey

2011

Doctor of Medicine, Hacettepe University

2004

3 Active

24-NHL-36-CB-PMC: An Observational Long-term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy (Long term follow-up to NHL 31)
Yalniz, F.
Caribou Biosciences Incorporated
6/3/24 → 6/3/26
Project: Research project
23-LEUK-23-CC: ACE-536-MF-002, A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK Inhibitor Therapy
Yalniz, F.
Celgene
11/27/23 → 11/27/25
Project: Research project
23-NHL-31-CB-PMC: CB-10A, A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Yalniz, F.
Caribou Biosciences Incorporated
9/8/23 → 9/8/25
Project: Research project